Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).PWS is a rare genetic disorder characterized by muscle weakness and feeding difficulties in infancy, followed by an insatiable hunger and tendency toward severe obesity starting in childhood. PWS also involves delayed development, intellectual disability, behavioral issues an ...